INDEPENDENT THINKING. BETTER EVIDENCE.WEIGHT, HEALTH & THE SCIENCE BETWEEN
WEIGHT-LOSS DRUG TRACKER

Orforglipron

Orforglipron is a nonpeptide oral GLP-1 receptor agonist. Its US brand Foundayo was approved in April 2026, so describing it as unapproved in the United States would be outdated.

A single official Foundayo orforglipron 0.8 mg bottle in its original US presentation.
Official Foundayo product photograph showing an orforglipron bottle in its US presentation. The pictured dose and packaging are not dosing advice. Image: Eli Lilly and Company. Official Foundayo media kit: https://www.lilly.com/news/media/foundayo

Orforglipron is a nonpeptide oral GLP-1 receptor agonist. Its US brand Foundayo was approved in April 2026, so describing it as unapproved in the United States would be outdated.

The cited approval concerns specified adults with obesity or overweight and a weight-related condition. It does not automatically establish every diabetes, age-group, cardiovascular, or jurisdictional use.

Foundayo and oral semaglutide are different molecules and products. Their administration requirements and evidence should be read separately, rather than treating an oral route as a dose-equivalence rule.

The FDA label contains important warnings, contraindications, and administration requirements. This record is a status guide and does not replace those instructions or provide a personal prescribing plan.

Regulatory status checked on 3 October 2026

United States: FDA approved Foundayo on 1 April 2026 for specified adult weight-management use alongside a reduced-calorie diet and increased activity. Current label restrictions apply.

European Union: The 14–17 September 2026 CHMP agenda lists orforglipron under assessment with outstanding issues. Subsequent EU marketing authorisation has not been verified.

Official records and primary evidence

Route and frequency describe approved product records or clinical-trial protocols as identified above. They are not instructions to use, obtain, combine, or dose a medicine. This record is informational and has not been independently medically reviewed.

Official references

  1. FDA Foundayo NDA approval letter ↗
  2. FDA Foundayo approved label ↗
  3. September 2026 CHMP draft agenda ↗

Clinical trial evidence

Registry status and published results are shown separately. Treatment averages across different studies are not a ranking or a prediction for an individual.

ATTAIN-1

NCT05869903 · Orforglipron profile

Sponsor
Eli Lilly and Company
Phase
Phase 3
Registry status
active not recruiting
Registry enrollment
3127 (actual)
Published analysis population
3127
Analysis time point
72 weeks
Population
Adults with obesity, or overweight with weight-related complications, without diabetes. Exact eligibility differs by trial; consult the linked protocol.
Registry checked
2026-10-03

Registry actual enrollment and published randomized population both equal 3127.

Published mean body-weight change at 72 weeks · treatment-regimen (intention-to-treat)
Historical trial armMean change from baseline
orforglipron 6 mg trial arm-7.5%
orforglipron 12 mg trial arm-8.4%
orforglipron 36 mg trial arm-11.2%
placebo-2.1%

Negative values indicate a decrease from baseline. Arm dose labels describe the research protocol, not a dosing recommendation.

Original study abstract · Full registry record

The original abstract and registry were checked; full texts and supplements were not independently reviewed. Confidence intervals absent from this record must not be inferred. These selected results do not describe every safety finding or subgroup.

Evidence, explainers and reporting

The medicine profile is a reference point. These articles address narrower questions and developments.

← Back to the drug tracker
Cookie policy